Search Results - "Greer, Jacqueline M"

A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms by Zeidner, Joshua F, Karp, Judith E, Blackford, Amanda L, Smith, B Douglas, Gojo, Ivana, Gore, Steven D, Levis, Mark J, Carraway, Hetty E, Greer, Jacqueline M, Ivy, S Percy, Pratz, Keith W, McDevitt, Michael A

“…Myeloproliferative neoplasms are a varied group of disorders that can have prolonged chronic phases, but eventually accelerate and can transform into a…”
Get full text

Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias by Karp, Judith E., Smith, B. Douglas, Resar, Linda S., Greer, Jacqueline M., Blackford, Amanda, Zhao, Ming, Moton-Nelson, Dwella, Alino, Katrina, Levis, Mark J., Gore, Steven D., Joseph, Biju, Carraway, Hetty, McDevitt, Michael A., Bagain, Lorena, Mackey, Karen, Briel, Janet, Doyle, L. Austin, Wright, John J., Rudek, Michelle A.

“…Flavopiridol is a protein bound, cytotoxic, cyclin-dependent kinase inhibitor. Flavopiridol given by 1-hour bolus at 50 mg/m2 daily 3 times followed by…”
Get full text

Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia by KARP, Judith E, GARRETT-MAYER, Elizabeth, LEVIS, Mark J, MCDEVITT, Michael A, CARRAWAY, Hetty E, PRATZ, Keith W, GLADSTONE, Douglas E, SHOWEL, Margaret M, OTHUS, Megan, DOYLE, L. Austin, WRIGHT, John J, PAGEL, John M, ESTEY, Elihu H, RUDEK, Michelle A, DOUGLAS SMITH, B, GREER, Jacqueline M, DRYE, D. Michelle, MACKEY, Karen, SHANNON DORCY, Kathleen, GORE, Steven D

“…Flavopiridol is a protein-bound, cytotoxic, cyclin dependent kinase inhibitor. A phase II trial of flavopiridol followed by ara-C and mitoxantrone with…”
Get full text

Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias by KARP, Judith E, THOMAS, Brian M, MACKEY, Karen, FRESHWATER, Tomoko, LEVIS, Mark J, MCDEVITT, Michael A, CARRAWAY, Hetty E, GLADSTONE, Douglas E, SHOWEL, Margaret M, LOECHNER, Sabine, PARRY, David A, HOROWITZ, Jo Ann, GREER, Jacqueline M, ISAACS, Randi, KAUFMANN, Scott H, SORGE, Christopher, GORE, Steven D, PRATZ, Keith W, DOUGLAS SMITH, B, FLATTEN, Karen S, PETERSON, Kevin, SCHNEIDER, Paula

“…Incorporation of cytarabine into DNA activates checkpoint kinase 1 (Chk1), which stabilizes stalled replication forks, induces S-phase slowing, and diminishes…”
Get full text

Population pharmacokinetics and site of action exposures of veliparib with topotecan plus carboplatin in patients with haematological malignancies by Mehrotra, Shailly, Gopalakrishnan, Mathangi, Gobburu, Jogarao, Greer, Jacqueline M., Piekarz, Richard, Karp, Judith E., Pratz, Keith, Rudek, Michelle A.

“…Aims Veliparib is a potent inhibitor of poly(ADP‐ribose) polymerase (PARP) enzyme. The objectives of the analysis were to evaluate the effect of baseline…”
Get full text

Population pharmacokinetics and exposure–response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias by Singh, Renu, Mehrotra, Shailly, Gopalakrishnan, Mathangi, Gojo, Ivana, Karp, Judith E., Greer, Jacqueline M., Chen, Alice, Piekarz, Richard, Kiesel, Brian F., Gobburu, Jogarao, Rudek, Michelle A., Beumer, Jan H.

“…Purpose Veliparib is an oral inhibitor of poly(ADP-ribose) polymerase enzyme. Combination of veliparib and temozolomide was well-tolerated and demonstrated…”
Get full text

Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients by LaCerte, Carl, Ivaturi, Vijay, Gobburu, Joga, Greer, Jacqueline M, Doyle, L Austin, Wright, John J, Karp, Judith E, Rudek, Michelle A

“…To elucidate any differences in the exposure-response of alvocidib (flavopiridol) given by 1-hour bolus or a hybrid schedule (30-minute bolus followed by a…”
Get full text

Exposure-Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies by Mehrotra, Shailly, Gopalakrishnan, Mathangi, Gobburu, Jogarao, Ji, Jiuping, Greer, Jacqueline M, Piekarz, Richard, Karp, Judith E, Pratz, Keith W, Rudek, Michelle A

“…A phase I trial of veliparib in combination with topotecan plus carboplatin (T+C) demonstrated a 33% objective response rate in patients with hematological…”
Get full text

Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure‐FLT3 Relationship by Liu, Tao, Ivaturi, Vijay, Sabato, Philip, Gobburu, Jogarao V. S., Greer, Jacqueline M., Wright, John J., Smith, B. Douglas, Pratz, Keith W., Rudek, Michelle A.

“…Sorafenib administered at the approved dose continuously is not tolerated long‐term in patients with acute myeloid leukemia (AML). The purpose of this study…”
Get full text

Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia by Karp, Judith E, Blackford, Amanda, Smith, B. Douglas, Alino, Katrina, Seung, Amy Hatfield, Bolaños-Meade, Javier, Greer, Jacqueline M, Carraway, Hetty E, Gore, Steven D, Jones, Richard J, Levis, Mark J, McDevitt, Michael A, Doyle, L. Austin, Wright, John J

“…Abstract Flavopiridol, a cyclin-dependent kinase inhibitor, is cytotoxic to leukemic blasts. In a Phase II study, flavopiridol 50 mg/m2 was given by 1-h…”
Get full text

Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide by Karp, Judith E., Flatten, Karen, Feldman, Eric J., Greer, Jacqueline M., Loegering, David A., Ricklis, Rebecca M., Morris, Lawrence E., Ritchie, Ellen, Smith, B. Douglas, Ironside, Valerie, Talbott, Timothy, Roboz, Gail, Le, Son B., Meng, Xue Wei, Schneider, Paula A., Dai, Nga T., Adjei, Alex A., Gore, Steven D., Levis, Mark J., Wright, John J., Garrett-Mayer, Elizabeth, Kaufmann, Scott H.

“…The farnesyltransferase inhibitor tipifarnib exhibits modest activity against acute myelogenous leukemia. To build on these results, we examined the effect of…”
Get full text

Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia by Karp, Judith E., Vener, Tatiana I., Raponi, Mitch, Ritchie, Ellen K., Smith, B. Douglas, Gore, Steven D., Morris, Lawrence E., Feldman, Eric J., Greer, Jacqueline M., Malek, Sami, Carraway, Hetty E., Ironside, Valerie, Galkin, Steven, Levis, Mark J., McDevitt, Michael A., Roboz, Gail R., Gocke, Christopher D., Derecho, Carlo, Palma, John, Wang, Yixin, Kaufmann, Scott H., Wright, John J., Garret-Mayer, Elizabeth

“…Tipifarnib (T) exhibits modest activity in elderly adults with newly diagnosed acute myelogenous leukemia (AML). Based on preclinical synergy, a phase 1 trial…”
Get full text

Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias by Zeidan, Amer M., Ricklis, Rebecca M., Carraway, Hetty E., Yun, Hyun D., Greer, Jacqueline M., Smith, B. Douglas, Levis, Mark J., McDevitt, Michael A., Pratz, Keith W., Showel, Margaret M., Gladstone, Douglas E., Gore, Steven D., Karp, Judith E.

“…Summary The prognosis of patients with relapsed and refractory acute leukaemia (RRAL) is very poor. Forty patients with RRAL were enroled [28 acute myeloid…”
Get full text

Escalation Trial of Clofarabine Followed by Escalating Dose of Fractionated Cyclophosphamide in Adults with Relapsed or Refractory Acute Leukemias by Zeidan, Amer M., Carraway, Hetty E, Yun, Hyun Don, Greer, Jacqueline M, Karp, Judith E.

“…Abstract 3615 The prognosis of patients with relapsed/refractory acute leukemias (RRAL) continues to be very poor, with a complete remission (CR) rate of ≤ 30%…”
Get full text

Phase I Dose-Escalation Study of SCH 900776 in Combination with Cytarabine (Ara-C) in Patients with Acute Leukemia by Thomas, Brian M., Kaufmann, Scott H., Greer, Jacqueline M, Gore, Steven D., Pratz, Keith W., Smith, B. Douglas, Mackey, Karen, Loechner, Sabine, Horowitz, Jo Ann, Karp, Judith E.

“…Abstract 1531 Checkpoint kinase (Chk1) is a serine-threonine kinase that is activated via phosphorylation in response to DNA damage and is critical to the…”
Get full text

Randomized Phase II Trial of Timed-Sequential Therapy (TST) with Flavopiridol (Alvocidib), Ara-C and Mitoxantrone (FLAM) Versus “7+3” for Adults Ages 70 Years and Under with Newly Diagnosed Acute Myeloid Leukemia (AML) by Zeidner, Joshua F., Gerber, Jonathan M., Blackford, Amanda, Litzow, Mark, Foster, Matthew C., Morris, Lawrence E., Gojo, Ivana, Lancet, Jeffrey E., Bose, Prithviraj, Tibes, Raoul, Strickland, Stephen A., Greer, Jacqueline M, Drye, Michelle, Meads, Kevin, Doyle, Austin, Little, Richard F, Wright, John J, Karp, Judith E.

“…Abstract 47 In adults with newly diagnosed, poor-risk AML we previously demonstrated that induction therapy with Flavopiridol in combination with Ara-C and…”
Get full text

Randomized Phase II Study of Two Schedules of Flavopiridol (Alvocidib, F) Given as Timed Sequential Therapy (TST) Wtih Ara-C and Mitoxantrone (FLAM) for Adults with Newly Diagnosed, Poor-Risk Acute Myelogenous Leukemia (AML) by Karp, Judith E., Pagel, John M., Smith, B. Douglas, Greer, Jacqueline M, Drye, D. Michelle, Smith, Kelly M., Dorcy, Kathleen, Wright, John J, Doyle, L. Austin, Garrett-Mayer, Elizabeth, Estey, Elihu H.

“…Abstract 186 Acute Myeloid Leukemia - Therapy, excluding Transplantation: Pediatric and Adult AML Therapy F is a protein bound, cytotoxic, cyclin dependent…”
Get full text

In Vivo Correlates of Response for Phase I Trial of Oral Tipifarnib (T) Combined with Oral Etoposide (E) for Adults Age ≥ 70 with Newly Diagnosed Acute Myelogenous Leukemia (AML) Who Are Not Candidates for Traditional Cytotoxic Chemotherapy (TCC) by Ricklis, Rebecca M., Karp, Judith E., Feldman, Eric J., Galkin, Suzanne, Greer, Jacqueline M., Ironside, Valerie, Mirjafary, Kim, Talbot, Timothy D., Morris, Lawrence E., Wright, John J., Kaufmann, Scott H.

“…T is a farnesyltransferase inhibitor with clinical activity in elderly adults with newly diagnosed AML who are not candidates for TCC. For adults age ≥ 65 with…”
Get full text